Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Marya Kozinova"'
Autor:
Shuai Ye, Dinara Sharipova, Marya Kozinova, Lilli Klug, Jimson D’Souza, Martin G. Belinsky, Katherine J. Johnson, Margret B. Einarson, Karthik Devarajan, Yan Zhou, Samuel Litwin, Michael C. Heinrich, Ronald DeMatteo, Margaret von Mehren, James S. Duncan, Lori Rink
Publikováno v:
JCI Insight, Vol 6, Iss 2 (2021)
Management of gastrointestinal stromal tumors (GISTs) has been revolutionized by the identification of activating mutations in KIT and PDGFRA and clinical application of RTK inhibitors in advanced disease. Stratification of GISTs into molecularly def
Externí odkaz:
https://doaj.org/article/bc77aa077101497c8a5b94060a37a94d
Autor:
Samuel Litwin, Karthik Devarajan, Yi Yu, Margaret von Mehren, Alex Campos, Shuai Ye, Brian Schwartz, Jeffrey M. Farma, Dinara Sharipova, Marya Kozinova, Sanjay S. Reddy, Shalina Joshi, Martin G. Belinsky, Lori Rink
Publikováno v:
Cancers
Volume 13
Issue 15
Cancers, Vol 13, Iss 3699, p 3699 (2021)
Volume 13
Issue 15
Cancers, Vol 13, Iss 3699, p 3699 (2021)
The majority of gastrointestinal stromal tumor (GIST) patients develop resistance to the first-line KIT inhibitor, imatinib mesylate (IM), through acquisition of secondary mutations in KIT or bypass signaling pathway activation. In addition to KIT, A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14928d4a6f8662972342e965bc14d5f3
https://pubmed.ncbi.nlm.nih.gov/34359600
https://pubmed.ncbi.nlm.nih.gov/34359600
Autor:
Alexander Metz, Marya Kozinova, Robert Uzzo, Jessica Peskin, Michael Slifker, Janusz Franco-Barraza, Edna Cukierman, Philip Abbosh
Publikováno v:
Cancer Research. 82:3725-3725
Introduction: SETD2 encodes a histone H3-K36 methyltransferase which is frequently inactivated in clear cell renal carcinomas (ccRCCs) and papillary RCCs via 3p deletion/LOH and deleterious mutations. Histone H3-K36 trimethylation is facilitated by S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c327062fb301bb3c2b8fea6294d9c838
https://doi.org/10.1158/1538-7445.am2022-3725
https://doi.org/10.1158/1538-7445.am2022-3725
Autor:
James S. Duncan, Yan Zhou, Katherine J. Johnson, Margaret von Mehren, Dinara Sharipova, Marya Kozinova, Ronald P. DeMatteo, Karthik Devarajan, Martin G. Belinsky, Michael Heinrich, Lilli Klug, Samuel Litwin, Shuai Ye, Lori Rink, Jimson W. D’Souza, Margret B. Einarson
Publikováno v:
JCI Insight, Vol 6, Iss 2 (2021)
JCI Insight
JCI Insight
Management of gastrointestinal stromal tumors (GISTs) has been revolutionized by the identification of activating mutations in KIT and PDGFRA and clinical application of RTK inhibitors in advanced disease. Stratification of GISTs into molecularly def
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d28c4dce33dae5e91c597b0243e832a3
https://doaj.org/article/bc77aa077101497c8a5b94060a37a94d
https://doaj.org/article/bc77aa077101497c8a5b94060a37a94d
Autor:
Yan Zhou, Katherine J. Johnson, Margret B. Einarson, Lilli Klug, Samuel Litwin, Dinara Sharipova, Shuai Ye, James S. Duncan, Martin G. Belinsky, Michael Heinrich, Lori Rink, Ronald P. DeMatteo, Jimson W. D’Souza, Marya Kozinova, Karthik Devarajan, Margaret von Mehren
Management of gastrointestinal stromal tumor (GIST) has been revolutionized by the identification of activating mutations in KIT and PDGFRA, and the clinical application of receptor tyrosine kinase (RTK) inhibitors in the advanced disease setting. St
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f7ba11688abbc6a10b2dbf843667139
https://doi.org/10.1101/2020.06.07.138693
https://doi.org/10.1101/2020.06.07.138693
Autor:
Marya Kozinova, Yi Yu, Shalina Joshi, Lori Rink, Jimson W. D’Souza, Reza Foroughi, Karthik Devarajan, Phillip Zook, Nestor F. Esnaola, Jeffrey M. Farma, Margaret von Mehren, Brian Schwartz, Terence Hall
Publikováno v:
Cancer Research. 78:4808-4808
The majority of gastrointestinal stromal tumors (GIST) harbor oncogenic mutations in the receptor tyrosine kinase KIT or platelet-derived growth factor receptor alpha (PDGFRA). Small molecule kinase inhibitors such as imatinib mesylate (IM) have sign
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e6e00183e8e81781f11bed2774c38c7
https://doi.org/10.1158/1538-7445.am2018-4808
https://doi.org/10.1158/1538-7445.am2018-4808